Sepracor Announces New Management Changes and Plans for Merger with Dainippon Sumitomo Pharma America
	FDA Extends PDUFA Action Date for STEDESA™ New Drug Application
	Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia
	Sepracor Granted Patent Term Extension for LUNESTA® and Provides Update on LUNESTA Pediatric Studies